Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon

US7402672B2 · kind B2 · utility

Assignee

• Aventis Pharmaceuticals Inc. · US

Inventors

• William Metz · Bound Brook, US
• Frank Halley · Romford, GB
• Gilles Dutruc-Rosset · Paris, FR
• Yong Mi Choi-Sledeski · Montgomery, US
• Gregory Bernard Poli · Perkasie, US
• David Fink · Lebanon, US
• Gilles Doerflinger · Les Ulis, FR
• Bao-Guo Huang · Cheektowaga, US
• Ann Gelormini · Cambridge, US
• Juan Antonio Gamboa · New York, US
• Andrew Giovanni · Flemington, US
• Joachim E. Roehr · Bernardsville, US
• Joseph T. Tsay · Bound Brook, US
• Fernando Camacho · Union, US
• William Joseph Hurst · Oxford, US
• Stephen Wayne Harnish · Wharton, US
• Yulin Chiang · Clay, US

Key dates

• Filing date: Dec 1, 2004
• Grant date: Jul 22, 2008
• Expiry date: Apr 12, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention discloses and claims compounds of formula (I)as inhibitors of human casein kinase IF, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.